Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 6/2015

01-06-2015 | Research Article

Oxidative stress associates with aggressiveness in lung large-cell carcinoma

Authors: Leonardo Lisboa da Motta, Marco Antonio De Bastiani, Fernanda Stapenhorst, Fábio Klamt

Published in: Tumor Biology | Issue 6/2015

Login to get access

Abstract

Oxidative stress is involved in many cancer-related processes; however, current therapeutics are unable to benefit from this approach. The lungs have a very exquisite redox environment that may contribute to the frequent and deadly nature of lung cancer. Very few studies specifically address lung large-cell carcinoma (LCC), even though this is one of the major subtypes. Using bioinformatic (in silico) tools, we demonstrated that a more aggressive lung LCC cell line (HOP-92) has an overall increase activity of the human antioxidant gene (HAG) network (P = 0.0046) when compared to the less aggressive cell line H-460. Gene set enrichment analysis (GSEA) showed that the expression of metallothioneins (MT), glutathione peroxidase 1 (GPx-1), and catalase (CAT) are responsible for this difference in gene signature. This was validated in vitro, where HOP-92 showed a pro-oxidative imbalance, presenting higher antioxidant enzymes (superoxide dismutase (SOD), CAT, and GPx) activities, lower reduced sulfhydryl groups and antioxidant potential, and higher lipoperoxidation and reactive species production. Also, HAG network is upregulated in lung LCC patients with worst outcome. Finally, the prognostic value of genes enriched in the most aggressive cell line was assessed in this cohort. Isoforms of metallothioneins are associated with bad prognosis, while the thioredoxin-interacting protein (TXNIP) is associated with good prognosis. Thus, redox metabolism can be an important aspect in lung LCC aggressiveness and a possible therapeutic target.
Appendix
Available only for authorised users
Literature
1.
Gorrini C, Harris IS, Mak TW. Modulation of oxidative stress as an anticancer strategy. Nat Rev Drug Discov. 2013;12:931–47.CrossRefPubMed
2.
Sayin VI, Ibrahim MX, Larsson E, Nilsson JA, Lindahl P, Bergo MO. Antioxidants accelerate lung cancer progression in mice. Sci Transl Med. 2014;6:221ra15.CrossRefPubMed
3.
Lisbôa da Motta L, Müller CB, De Bastiani MA, Behr GA, França FS, da Rocha RF, et al. Imbalance in redox status is associated with tumor aggressiveness and poor outcome in lung adenocarcinoma patients. J Cancer Res Clin Oncol. 2014;140:461–70.CrossRefPubMed
4.
Filaire E, Dupuis C, Galvaing G, Aubreton S, Laurent H, Richard R, et al. Lung cancer: what are the links with oxidative stress, physical activity and nutrition. Lung Cancer. 2013;82:383–9.CrossRefPubMed
5.
Marikovsky M, Nevo N, Vadai E, Harris-Cerruti C. Cu/Zn superoxide dismutase plays a role in angiogenesis. Int J Cancer. 2002;97:34–41.CrossRefPubMed
6.
Connor KM, Hempel N, Nelson KK, Dabiri G, Gamarra A, Belarmino J, et al. Manganese superoxide dismutase enhances the invasive and migratory activity of tumor cells. Cancer Res. 2007;67:10260–7.CrossRefPubMed
7.
Pani G, Galeotti T, Chiarugi P. Metastasis: cancer cell’s escape from oxidative stress. Cancer Metastasis Rev. 2010;29:351–78.CrossRefPubMed
8.
Sotgia F, Martinez-Outschoorn UE, Lisanti MP. Mitochondrial oxidative stress drives tumor progression and metastasis: should we use antioxidants as a key component of cancer treatment and prevention? BMC Med. 2011;9:62.CrossRefPubMedPubMedCentral
9.
Greenberg AK, Tsay J-C, Tchou-Wong K-M, Jorgensen A, Rom WN. Chemoprevention of lung cancer: prospects and disappointments in human clinical trials. Cancers (Basel). Multidisciplinary Digital Publishing Institute. 2013;5:131–48.
10.
Valavanidis A, Vlachogianni T, Fiotakis K, Loridas S. Pulmonary oxidative stress, inflammation and cancer: respirable particulate matter, fibrous dusts and ozone as major causes of lung carcinogenesis through reactive oxygen species mechanisms. Int J Environ Res Public Health. 2013;10:3886–907.CrossRefPubMedPubMedCentral
11.
Rahman I, Biswas SK, Kode A. Oxidant and antioxidant balance in the airways and airway diseases. Eur J Pharmacol. 2006;533:222–39.CrossRefPubMed
12.
Ilonen IK, Räsänen JV, Sihvo EI, Knuuttila A, Salmenkivi KM, Ahotupa MO, et al. Oxidative stress in non-small cell lung cancer: role of nicotinamide adenine dinucleotide phosphate oxidase and glutathione. Acta Oncol. 2009;48:1054–61.CrossRefPubMed
13.
Esme H, Cemek M, Sezer M, Saglam H, Demir A, Melek H, et al. High levels of oxidative stress in patients with advanced lung cancer. Respirology. 2008;13:112–6.CrossRefPubMed
14.
Ho JC, Chan-Yeung M, Ho SP, Mak JC, Ip MS, Ooi GC, et al. Disturbance of systemic antioxidant profile in nonsmall cell lung carcinoma. Eur Respir J. 2007;29:273–8.CrossRefPubMed
15.
Kaynar H, Meral M, Turhan H, Keles M, Celik G, Akcay F. Glutathione peroxidase, glutathione-S-transferase, catalase, xanthine oxidase, Cu-Zn superoxide dismutase activities, total glutathione, nitric oxide, and malondialdehyde levels in erythrocytes of patients with small cell and non-small cell lung cancer. Cancer Lett. 2005;227:133–9.CrossRefPubMed
16.
Melloni B, Lefebvre MA, Bonnaud F, Vergnenègre A, Grossin L, Rigaud M, et al. Antioxidant activity in bronchoalveolar lavage fluid from patients with lung cancer. Am J Respir Crit Care Med. 1996;154:1706–11.CrossRefPubMed
17.
Chan HP, Tran V, Lewis C, Thomas PS. Elevated levels of oxidative stress markers in exhaled breath condensate. J Thorac Oncol. 2009;4(2):172–8.CrossRefPubMed
18.
Jaruga P, Zastawny TH, Skokowski J, Dizdaroglu M, Olinski R. Oxidative DNA base damage and antioxidant enzyme activities in human lung cancer. FEBS Lett. 1994;341:59–64.CrossRefPubMed
19.
Coursin DB, Cihla HP, Sempf J, Oberley TD, Oberley LW. An immunohistochemical analysis of antioxidant and glutathione S-transferase enzyme levels in normal and neoplastic human lung. Histol Histopathol. 1996;11:851–60.PubMed
20.
Blair SL, Heerdt P, Sachar S, Abolhoda A, Hochwald S, Cheng H, et al. Glutathione metabolism in patients with non-small cell lung cancers. Cancer Res. 1997;57:152–5.PubMed
21.
Brennan P, Fortes C, Butler J, Agudo A, Benhamou S, Darby S, et al. A multicenter case-control study of diet and lung cancer among non-smokers. Cancer Causes Control. 2000;11:49–58.CrossRefPubMed
22.
23.
Kerr KM. Classification of lung cancer: proposals for change? Arch Pathol Lab Med. 2012;136:1190–3.CrossRefPubMed
24.
Pardo J, Martinez-Peñuela AM, Sola JJ, Panizo A, Gúrpide A, Martinez-Peñuela JM, et al. Large cell carcinoma of the lung: an endangered species? Appl Immunohistochem Mol Morphol. 2009;17:383–92.CrossRefPubMed
25.
Rossi G, Mengoli MC, Cavazza A, Nicoli D, Barbareschi M, Cantaloni C, et al. Large cell carcinoma of the lung: clinically oriented classification integrating immunohistochemistry and molecular biology. Virchows Arch. 2014;464(1):61–8.CrossRefPubMed
26.
Travis WD, Brambilla E, Riely GJ. New pathologic classification of lung cancer: relevance for clinical practice and clinical trials. J Clin Oncol. 2013;31:992–1001.CrossRefPubMed
27.
Vichai V, Kirtikara K. Sulforhodamine B colorimetric assay for cytotoxicity screening. Nat Protoc. 2006;1:1112–6.CrossRefPubMed
28.
Gelain DP, Dalmolin RJS, Belau VL, Moreira JCF, Klamt F, Castro MAA. A systematic review of human antioxidant genes. Front Biosci. 2009;14:4457–63.CrossRef
29.
Castro MAA, Filho JLR, Dalmolin RJS, Sinigaglia M, Moreira JCF, Mombach JCM, et al. ViaComplex: software for landscape analysis of gene expression networks in genomic context. Bioinformatics. 2009;25:1468–9.CrossRefPubMed
30.
Castro MAA, Mombach JCM, de Almeida RMC, Moreira JCF. Impaired expression of NER gene network in sporadic solid tumors. 2007;35:1859–67.
31.
Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL. Gene set enrichment analysis : A knowledge-based approach for interpreting genome-wide. Proc Natl Acad Sci U S A. 2005;102(43):15545–50.CrossRefPubMedPubMedCentral
32.
Misra HP, Fridovich I. The role of superoxide anion in the autoxidation of epinephrine and a simple assay for superoxide dismutase. J Biol Chem. 1972;247:3170–5.PubMed
33.
34.
Dresch MTK, Rossato SB, Kappel VD, Biegelmeyer R, Hoff MLM, Mayorga P, et al. Optimization and validation of an alternative method to evaluate total reactive antioxidant potential. Anal Biochem. 2009;385:107–14.CrossRefPubMed
35.
Sak A, Stuschke M, Groneberg M, Kübler D, Pöttgen C, Eberhardt WEE. Inhibiting the aurora B kinase potently suppresses repopulation during fractionated irradiation of human lung cancer cell lines. Int J Radiat Oncol Biol Phys. 2012;84:492–9.CrossRefPubMed
36.
Saintigny P, Peng S, Zhang L, Sen B, Wistuba II, Lippman SM, et al. Global evaluation of Eph receptors and ephrins in lung adenocarcinomas identifies EphA4 as an inhibitor of cell migration and invasion. Mol Cancer Ther. 2012;11:2021–32.CrossRefPubMedPubMedCentral
37.
Wang D, Xiang D-B, Yang X-Q, Chen L-S, Li M-X, Zhong Z-Y, et al. APE1 overexpression is associated with cisplatin resistance in non-small cell lung cancer and targeted inhibition of APE1 enhances the activity of cisplatin in A549 cells. Lung Cancer. 2009;66:298–304.CrossRefPubMed
38.
Yoo DG, Song YJ, Cho EJ, Lee SK, Park JB, Yu JH, et al. Alteration of APE1/ref-1 expression in non-small cell lung cancer: the implications of impaired extracellular superoxide dismutase and catalase antioxidant systems. Lung Cancer. 2008;60:277–84.CrossRefPubMed
39.
40.
Klamt F, Shacter E. Taurine chloramine, an oxidant derived from neutrophils, induces apoptosis in human B lymphoma cells through mitochondrial damage. J Biol Chem. 2005;280:21346–52.CrossRefPubMed
41.
42.
Cherian M. Metallothioneins in human tumors and potential roles in carcinogenesis. Mutat Res Mol Mech Mutagen. 2003;533:201–9.CrossRef
43.
Lincoln DT, Ali Emadi EM, Tonissen KF, Clarke FM. The thioredoxin-thioredoxin reductase system: over-expression in human cancer. Anticancer Res. 2003;23:2425–33.PubMed
44.
Rotblat B, Grunewald TGP, Leprivier G, Melino G, Knight RA. Anti-oxidative stress response genes: bioinformatic analysis of their expression and relevance in multiple cancers. Oncotarget. 2013;4(12):2577–90.CrossRefPubMedPubMedCentral
45.
Cadenas C, Franckenstein D, Schmidt M, Gehrmann M, Hermes M, Geppert B, et al. Role of thioredoxin reductase 1 and thioredoxin interacting protein in prognosis of breast cancer. Breast Cancer Res. 2010;12:R44.CrossRefPubMedPubMedCentral
46.
47.
Lim JY, Yoon SO, Hong SW, Kim JW, Choi SH, Cho JY. Thioredoxin and thioredoxin-interacting protein as prognostic markers for gastric cancer recurrence. World J Gastroenterol. 2012;18:5581–8.CrossRefPubMedPubMedCentral
48.
Morrison JA, Pike LA, Sams SB, Sharma V, Zhou Q, Severson JJ, et al. Thioredoxin interacting protein (TXNIP) is a novel tumor suppressor in thyroid cancer. Mol Cancer. 2014;13:62.CrossRefPubMedPubMedCentral
49.
Nishinaka Y. Loss of thioredoxin-binding protein-2/vitamin D3 up-regulated protein 1 in human T-cell leukemia virus type I-dependent T-cell transformation: implications for adult T-cell leukemia leukemogenesis. Cancer Res. 2004;64:1287–92.CrossRefPubMed
50.
Nishizawa K, Nishiyama H, Matsui Y, Kobayashi T, Saito R, Kotani H, et al. Thioredoxin-interacting protein suppresses bladder carcinogenesis. Carcinogenesis. 2011;32:1459–66.CrossRefPubMed
51.
Burhans WC, Heintz NH. The cell cycle is a redox cycle: linking phase-specific targets to cell fate. Free Radic Biol Med. 2009;47:1282–93.CrossRefPubMed
52.
Policastro L, Molinari B, Larcher F, Blanco P, Podhajcer OL, Costa CS, et al. Imbalance of antioxidant enzymes in tumor cells and inhibition of proliferation and malignant features by scavenging hydrogen peroxide. Mol Carcinog. 2004;39:103–13.CrossRefPubMed
53.
Ibañez IL, Policastro LL, Tropper I, Bracalente C, Palmieri MA, Rojas PA, et al. H2O2 scavenging inhibits G1/S transition by increasing nuclear levels of p27KIP1. Cancer Lett. 2011;305:58–68.CrossRefPubMed
54.
Goh J, Enns L, Fatemie S, Hopkins H, Morton J, Pettan-Brewer C, et al. Mitochondrial targeted catalase suppresses invasive breast cancer in mice. BMC Cancer. 2011;11:191.CrossRefPubMedPubMedCentral
55.
Nishikawa M, Hashida M, Takakura Y. Catalase delivery for inhibiting ROS-mediated tissue injury and tumor metastasis. Adv Drug Deliv Rev. 2009;61:319–26.CrossRefPubMed
Metadata
Title
Oxidative stress associates with aggressiveness in lung large-cell carcinoma
Authors
Leonardo Lisboa da Motta
Marco Antonio De Bastiani
Fernanda Stapenhorst
Fábio Klamt
Publication date
01-06-2015
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 6/2015
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-015-3116-9

Other articles of this Issue 6/2015

Tumor Biology 6/2015 Go to the issue

Research Article

Nicotinamide induces apoptosis of F9 mouse teratocarcinoma stem cells by downregulation of SATB1 expression

Research Article

A polysaccharide from Glycyrrhiza inflata Licorice inhibits proliferation of human oral cancer cells by inducing apoptosis via mitochondrial pathway

Research Article

High serum microRNA-122 level is independently associated with higher overall survival rate in hepatocellular carcinoma patients

Research Article

Activation of M3 muscarinic receptor by acetylcholine promotes non-small cell lung cancer cell proliferation and invasion via EGFR/PI3K/AKT pathway

Research Article

Clinical significance of Sam68 expression in endometrial carcinoma

Research Article

Genetic polymorphisms in antioxidant enzyme genes and susceptibility to hepatocellular carcinoma in Chinese population: a case-control study
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits